Innovator firms have deployed several tactics to derail uptake of biosimilars in the US, including whisper campaigns that allege such drugs are inferior to interchangeable products and their original reference drugs, and contracting that threatens the loss of rebates on other products if a biosimilar is placed on a formulary.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?